BioProcess International European Conference and Exhibition
10 Apr 2007

During the past 26 years Amgen has grown from a start-up organisation to a fully integrated biopharmaceutical company of almost 20,000 with sales of over $12B annually. So how did it get to where it is today?

This is a challenge that many biopharmaceutical companies strive to achieve. How Amgen overcame these challenges which resulted in its prominent growth, are explained by Dr James Thomas, the Vice President in the Process and Analytical Sciences Department in the USA. He will place a special emphasis on how the company has created both a rich pipeline and the commercial infrastructure required to get products into the hands of patients.

You can hear Dr James Thomas present his view on the challenges Amgen has faced at this years BioProcess International European Conference 24th April 2007, He is a plenary speaker on Day 1 at 9.05.

For more information please visit the article webpage. 

Request Info

Company website

Informa Life Sciences

Write a Review

Join the Global SelectScience Community Today! It’s FREE!

Helping you make informed decisions about the latest lab products and technologies:

  • Be the first to learn about new technologies
  • 10,000+ trusted product reviews from your peers
  • Compare 500,000 products and manufacturers
  • Get exclusive buying tips from experts
  • Find solutions fast: 10,000+ Application Notes, Webinars and Videos

Connect with 250,000 scientists... All in one place!

Become a member today!